Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed among 196 allogeneic stem cell transplant recipients within a 29-month period. Recipients of unrelated stem cell transplants were at higher risk. All patients received foscarnet; 8 subsequently received cidofovir. Strains were initially foscarnet-resistant in 3 patients and secondarily so in 4 patients. In vitro resistance to acyclovir or foscarnet was associated with clinical failure of these drugs; however, in vitro susceptibility to foscarnet was associated with complete response in only 5 of 7 patients. No strain from any of the 7 patients was resistant in vitro to cidofovir; however, only 3 of 7 patients achieved complete response. Therefore, acyclovir-and/or foscarnet-resistant HSV-1 infections after allogeneic stem cell transplantation have become a concern; current strategies need to be reassessed and new strategies must be evaluated in this setting.
varied according to the underlying disease and the type of transplant. The standard conditioning for receiving genoidentical transplants (i.e., matched related transplants) was as follows. Patients with myeloid leukemia received cyclophosphamide (120-200 mg/ kg) and either fractionated total body irradiation (12 Gy in 6 doses) or busulfan (16 mg/kg). Patients with acute lymphoblastic leukemia received a combination of fractionated total body irradiation, cytosine arabinoside (12-18 g/m 2 ), and melphalan (140 mg/m 2 ). Patients with idiopathic aplastic anemia received antithymocyte globulin (15 mg/kg/day for 5 days) and cyclophosphamide (200 mg/ kg). Recipients of unrelated grafts were usually conditioned with antithymocyte globulin (15 mg/kg/day for 5-6 days), cyclophosphamide (120 mg/kg), thiotepa (10 mg/kg), and fractionated total body irradiation. Patients with Fanconi's anemia were conditioned with reduced doses.
Prophylaxis for graft-versus-host disease (GVHD) usually consisted of iv cyclosporin A (3 mg/kg/day, started 2 days before the day of transplantation) and iv methotrexate (15 mg/m 2 at day 1 and 10 mg/m 2 at days 3, 6, and 11 after transplantation). According to current protocols, some recipients of unrelated marrow received a T cell-depleted graft, achieved by positive selection of CD34 cells, and cyclosporin A. Finally, cord blood transplant recipients were given cyclosporin A and high-dose steroids with a progressive taper. Acute GVHD was graded as stage 1-4 by use of standard criteria [13] , and chronic GVHD was assessed as being absent, limited, or extensive [14] .
Baseline serological evaluation of stem cell transplant recipients included testing for cytomegalovirus (CMV), hepatitis C virus, hepatitis B virus, HIV, and human T cell lymphotropic virus type 1. HSV serology was not performed routinely. However, for the patients who developed proven acyclovir-resistant HSV infection, baseline HSV-1 and HSV-2 serological evaluations were done ret-rospectively on serum stored from before transplantation. At entry, anti-infectious prophylaxis consisted of amoxicillin and either pefloxacin or ofloxacin against bacteria, fluconazole and oral amphotericin B against fungi, and trimethoprim-sulfamethoxazole or sulfadoxine-pyrimethamine against Pneumocystis carinii and Toxoplasma gondii. Prophylactic polyvalent immune globulins were administered from day 10 before stem cell transplantation to day 100 after transplantation at doses ranging from 100 to 500 mg/kg/ week. All patients received prophylaxis against HSV with oral (or iv, when oral intake was impossible) acyclovir at a dose ranging from 500 to 1000 mg/m 2 /day from day 10 before transplant. All anti-infectious agents, except prophylactic amoxicillin, trimethoprim-sulfamethoxazole or sulfadoxine-pyrimethamine, and acyclovir, were stopped when the absolute neutrophil count exceeded 500 cells/mm 3 and provided that active GVHD was absent. After discharge, HSV prophylaxis consisted of oral acyclovir (200 mg 5 times daily) or, in a few cases, valacyclovir, 500 mg b.i.d. In most cases, antiherpetic prophylaxis was continued until prednisolone was discontinued. CMV pp65 antigenemia was assessed weekly until day 100 and then on the basis of clinical findings. CMV infection was defined as the detection of CMV antigen-positive cells (у2 per 200,000 leukocytes). The majority of patients who had CMV infection received ganciclovir as an initial preemptive therapy for 2-3 weeks. Some patients with neutropenia received foscarnet as first-line therapy. CMV disease was treated by ganciclovir and/or foscarnet with high-dose polyvalent immune globulins. Acyclovir was transiently stopped if the patient was treated with ganciclovir or foscarnet for CMV infection or disease.
The medical records were reviewed for all patients who underwent transplantation from 1 November 1996 through 31 March 1999 and for those who developed an acyclovir-resistant HSV-1 infection following transplantation. HSV antiviral susceptibility testing became routinely available beginning November 1996. During this 29-month period, 196 allogeneic stem cell transplantations were performed: 111 were genoidentical and 85 were non-genoidentical, including 77 unrelated and 8 mismatched related. Among the non-genoidentical transplants, 34 were T cell-depleted by CD34-positive selection.
Definitions of HSV-1 infections and antiviral strategies. An HSV-1 infection, or episode, was defined as the appearance of suggestive clinical signs combined with a virologically proven HSV-1 infection. The first day of clinical manifestation of oropharyngeal HSV infection was designated as the day when typical HSV lesions were observed.
Before March 1997, if a patient was receiving acyclovir prophylaxis and had a progressive herpetic lesion, the usual therapeutic scheme was first to increase the dose of iv acyclovir to a maximum of 1500 mg/m 2 /day. If there was no response, the next step was to switch to foscarnet (180 mg/kg/day). Because acyclovir was consistently ineffective in this setting, patients treated after March 1997 received foscarnet as initial curative therapy, with or without concomitant acyclovir. Intravenous cidofovir (5 mg/kg per dose) was prescribed in case of foscarnet clinical failure, especially if antiviral susceptibility testing also indicated that the HSV-1 isolate showed resistance or intermediate resistance to foscarnet. If the patients responded, treatments were continued until the lesions healed, with additional maintenance therapy of varying duration.
Nine patients received at least 1 course of topical treatment (acyclovir, 1 patient; trifluridine, 2, vidarabine, 6) of varying duration.
None of the patients responded. This modality is not further discussed.
In addition, when patients developed lesions while they were not receiving antiviral prophylaxis, the diagnosis of herpetic infection was made only on clinical grounds. In such cases, empirical acyclovir or valacyclovir was given, and usually no further virological investigation was done if the lesion healed.
A complete clinical response was defined as the disappearance of all clinical signs and symptoms related to the infection. A partial clinical response was defined as an improvement of signs and symptoms 150%. Otherwise the outcome was considered as failure.
Culture and antiviral susceptibility testing of HSV isolates. Asymptomatic shedding of HSV was not looked for. Specimens for culture were obtained from oral, ocular, and genital lesions or from bronchoalveolar lavage product and inoculated onto human diploid fibroblast cells . Duplicate cultures were allowed to progress to complete HSV-specific cytopathic effect. Virus typing was done on infected cell cultures by use of monoclonal antibodies against HSV-1 and HSV-2 (MicroTrak Syva, Palo Alto, CA). Virus strains were sent to the Department of Virology (Laboratoire de Virologie) in Hospices Civils de Lyon for antiviral susceptibility testing. Antiviral susceptibilities were determined with a chessboard titration of each virus strain, allowing simultaneous titration of the virus with various concentrations of antiviral drug and without antiviral drug. Susceptibilities to acyclovir (Glaxo Wellcome, Greenford, UK) and foscarnet (Astra Pharmaceutical Products, Westboro, MA) were done on Vero cells (African Green monkey kidney cells); viral multiplication was checked after 2 days at 36ЊC with a dye-uptake assay, as described elsewhere [15] . Cidofovir susceptibility was assessed on MRC-5 cells; viral multiplication was checked by an ELISA after 2 days at 36ЊC. The antibodies, rabbit HSV-1 or -2 antisera (Dako, Copenhagen), were revealed with protein A-peroxidase conjugate (Bio-Rad Laboratories, Richmond, CA). Optical density values, obtained at 405 nm for dye-uptake assay and 540 nm for ELISA, were used with the Biolise program (Life Sciences International, St. Petersburg, FL) to calculate the concentration of the drug causing a 50% inhibition of viral replication (IC 50 ). Cutoff values for antiviral resistance were 6.5 mM for acyclovir, 400 mM for foscarnet, and 10-15 mM for cidofovir. HSV-1 isolates for which the foscarnet IC 50 was between 300 and 400 mM were classified as having intermediate resistance. Results for viral resistance assays were available to clinicians within 1-2 weeks.
Results
Patient characteristics. Table 1 shows patient characteristics at baseline, and table 2 shows characteristics at the time of the first resistant HSV-1 episode.
During the 29-month study period, 14 cases of acyclovirresistant HSV-1 infections were diagnosed, including 6 cases that exhibited resistance to both acyclovir and foscarnet and 1 case that showed foscarnet resistance and then acyclovir resistance. These patients represent 7% (14/196 ) of the population undergoing transplantation.
Acyclovir-resistant HSV-1 infections were significantly more frequently diagnosed in patients who received nongenoidentical ). The CD4 lymphocyte count was assessed at least once for 8 patients during the first 4 months after transplantation and ranged from 0 to 27 cells/mm 3 (median, 1 cell/mm 3 ; data not shown). At the time of the first resistant HSV episode, acute grade у2 GVHD had occurred or was present in only 5 (36%) of 14 patients. Acute grade у2 GVHD occurred subsequently in 1 additional patient and extensive chronic GVHD in 3 other patients. In the 182 other patients who underwent transplantation during the same period, acute grade у2 GVHD occurred in 95 (52%) at a median time of 17 days after transplantation, and extensive chronic GVHD developed in 57 (31%) of 127 patients who survived to at least 100 days. The median steroid dose at time of HSV-1 infection was 1.1 mg/kg (range, 0-2.8 mg/kg).
Clinical findings at the first episode. The median interval between stem cell transplantation and the first clinical manifestation of acyclovir-resistant HSV-1 infection was 32 days (range, 11-139 days; table 2). Eleven patients developed extensive oropharyngeal ulcers as initial manifestations of the HSV-1 episode. Oropharyngeal involvement was associated with herpetic interstitial pneumonitis in 1 patient and with specific ulcerations of nostril and fingers in another patient. In 9 patients, acyclovir-induced mucositis had healed before the reappearance of oral lesions caused by acyclovir-resistant HSV-1, whereas in 2 patients, the history of mucositis was not clinically distinct from herpetic oropharyngeal episode. The initial presentation in the 3 other patients was keratitis, perineal infection, or rectal infection.
Prophylactic acyclovir had been given for a median duration of 42 days (range, 22-68 days) before the development of resistant herpetic disease.
Treatment of the first episode. The median duration of antiherpetic curative treatment was 42 days (range, 7-208 days; table 3table 3). Monotherapy with high-dose (1500 mg/m 2 /day) iv acyclovir was given as first-line treatment to 5 patients who were receiving either oral acyclovir or iv low-dose acyclovir. Another patient was given oral acyclovir (1200 mg/day) because he was not receiving antiviral prophylaxis when the HSV-1 episode occurred. All 14 patients in this series received foscarnet therapy. Foscarnet was given as first-line treatment to 8 patients, with concomitant iv acyclovir to 2 patients. Six additional patients received foscarnet after failure of iv high-dose acyclovir or of oral acyclovir. Cidofovir was given to 5 patients after failure of foscarnet, to 2 partial responders to foscarnet, and as maintenance therapy to 1 additional patient, who was in complete response after foscarnet.
Clinical outcomes and correlation with in vitro HSV-1 antiviral susceptibility in the first episode. The median time from stem cell transplantation to first recovery of an HSV-1 isolate was 42 days (range, 11-170 days; table 3).
All initial HSV-1 strains isolated during the first episode from the 13 patients receiving acyclovir prophylaxis were acyclovirresistant in vitro. In vitro resistance to acyclovir was always associated with clinical failure of iv high-dose acyclovir. Discontinuation of acyclovir or valacyclovir was followed by the appearance of acyclovir susceptibility in isolates from 2 of 8 patients; serial isolates were recovered from these 2 patients after 75 days and 125 days. Both patients had received foscarnet, followed by cidofovir.
Isolates from 7 patients showed sustained in vitro susceptibility to foscarnet, which was associated with complete response in 5 of 7 patients, with partial response in 1 patient, and with treatment failure in 1 patient. Isolates from 2 other patients showed early occurrence of secondary in vitro resistance to foscarnet after the patients had been treated with foscarnet for 5 and 7 days; foscarnet treatment failed for both patients. Isolates from 1 other patients showed late secondary in vitro resistance 48 days after the initiation of foscarnet; this patient responded partially to this drug. Intermediate resistance in vitro was seen in the first isolate from another patient (patient 14) who had previously received a 39-day course of foscarnet for treatment of CMV infection. Foscarnet therapy failed for this last patient. In 3 other patients, a pattern of full (1 patient) or intermediate (2 patients) primary resistance to foscarnet was observed; foscarnet therapy failed for all of these patients. In patients from who serial isolates were available, in vitro resis- tance was reversed in 1 (19 days after foscarnet discontinuation) and was maintained in 4 others.
Isolates from 7 patients were tested for in vitro susceptibility to cidofovir. Although none showed resistance to cidofovir in vitro, 3 patients had complete response to cidofovir therapy, 2 had partial response, and therapy failed for 2. Susceptibility testing was not done for the 8th patient who received cidofovir treatment, which subsequently failed.
Subsequent episodes. Among the 8 patients who did not die during the first episode of HSV-1 disease, 5 had a second episode at a median of 45 days (range, 13 to 81 days) after discontinuation of a previous successful therapy (table 3) . Firstline treatment consisted of readministration of acyclovir (oral or iv) or valacyclovir to all 5 patients; this treatment was successful for 3 patients. For patient 12, valacyclovir therapy was interrupted by 1 course of ganciclovir for CMV infection; however, the lesion disappeared only after valacyclovir was resumed. Cidofovir was given to 2 patients after failure of acyclovir or valacyclovir therapy, which resulted in partial response in 1 patient. However, for this latter patient (patient 11), cidofovir was discontinued when CMV disease occurred and treatment was switched to foscarnet and ganciclovir. Finally, 1 patient experienced a 3rd episode of disease and was successfully treated with foscarnet after iv acyclovir therapy failed.
In 3 cases, the correlation between in vitro HSV-1 antiviral susceptibility and clinical outcome could be evaluated. Whereas a good correlation between in vitro HSV-1 antiviral susceptibility results and clinical response was observed in 2 cases, there was a discrepancy in the 3rd case (patient 12). Patient 12 developed a limited lingual ulcer while receiving valacyclovir prophylaxis; the HSV-1 isolate was initially susceptible in vitro to acyclovir. Although subsequent isolates became acyclovir-resistant, the lesion ultimately healed with valacyclovir therapy.
Other viral infections. CMV infection and/or disease occurred in 4 of 14 patients with proven acyclovir-resistant HSV-1 disease, versus 69 of the other 182 patients ( , x 2 test). P p .49 Only 2 of 14 patients received anti-CMV therapy before the first episode of resistant HSV infection (1 received ganciclovir followed by foscarnet, the other ganciclovir).
Epstein-Barr virus-associated lymphoproliferation (with concomitant adenovirus disease in 1 patient) occurred in 2 of the 14 patients in this series (at days 62 and 114 after transplantation), compared with 3 of 182 ( , Fisher's P p .042 test) in the other patient group (at days 56, 90, and 90 after transplantation).
Survival and causes of death. As of 30 June 1999, there were 10 deaths among the 14 patients in this study (table 3) . The Kaplan-Meier estimate of 1-year survival was 25% ‫ע‬ for these 14 patients, compared with for the 24% 50% ‫ע‬ 8% 182 patients who underwent transplantation during the same period ( , log rank test). If only unrelated transplants P p .22 were considered, the Kaplan-Meier estimate of 1-year survival for the 13 patients of this series was , compared 27% ‫ע‬ 24% with for the 64 patients who underwent trans-40% ‫ע‬ 12% plantation during the same period ( , log rank test). P p .97 Resistant HSV-1 infection was clearly implicated in the deaths of 2 patients (1 from interstitial pneumonia and 1 from a tracheobronchial clot obstruction caused by profuse oropharyngeal bleeding that was related to the herpetic infection). Resistant HSV-1 infection was not healed at time of death in 5 other patients and was extensive in 2 of these patients. Autopsies were not performed.
Discussion
HSV clinical isolates are generally resistant to acyclovir because the activity of the virus-encoded thymidine kinase is deficient. Exposure to acyclovir provides an ideal environment for selection of such variants, which exist naturally in the wild HSV population. Thymidine kinase mutants are cross-resistant to ganciclovir and to famciclovir but sensitive to foscarnet and cidofovir [10] . A less common mechanism of resistance is an alteration in the HSV-specified DNA polymerase (pol), which can confer single resistance to either acyclovir or foscarnet, or double resistance to both acyclovir and foscarnet [16] . On the other hand, double mutants with alterations in both HSV thymidine kinase activity and DNA polymerase function can occur, resulting in double resistance to both acyclovir and foscarnet. Laboratory-derived cidofovir-resistant HSV strains contain mutations in nonconserved regions of the polymerase gene but do not have cross-resistance to acyclovir or foscarnet [17] . Factors that predispose HIV-infected subjects to infection with acyclovir-resistant HSV are profound immunosuppression (CD4 cell count !50 cells/mm 3 ) and a longer duration of herpetic lesions and of acyclovir therapy [8, [18] [19] [20] . In the present study, isolates resistant to acyclovir were observed after a median duration of acyclovir treatment of only 42 days. Foscarnet resistance has been described in isolates from immunocompromised patients only, mostly after previous foscarnet therapy [21, 22] . In our study, a striking finding was that infections caused by HSV-1 strains were primarily resistant to foscarnet in 3 unrelated stem cell transplant recipients.
In the early 1980s, acyclovir-resistant HSV-1 infections were studied in allogeneic stem cell transplant recipients who were receiving acyclovir prophylaxis; they seemed to be infrequent and mild [6] . Subsequently, such infections have been increasingly reported, and some have caused severe morbidity [7] [8] [9] [10] [11] [12] [23] [24] [25] [26] [27] [28] . Overall, ∼40 laboratory-proven acyclovir-resistant HSV infections in stem cell transplant recipients have been reported. A few of these cases, all caused by HSV-1, displayed laboratoryproven double resistance to acyclovir and foscarnet. One patient had received an unrelated T cell-depleted bone marrow transplant [29] , and another had received an unrelated cord blood transplant [30] . More recently, another group reported 3 additional patients with such a double-resistant infection [12] .
We report 14 cases of laboratory-proven acyclovir-resistant HSV-1 infection, including 6 (43%) with combined resistance to acyclovir and foscarnet. The rate of resistant HSV-1 infections during this recent 29-month period was 7% in the entire population (15% in the non-genoidentical transplant population). This is higher than previously observed in our unit: From January 1991 through October 1996, 407 transplantations were performed (73% were genoidentical) and only 6 HSV infections were clinically suspected to be acyclovir-resistant (1.5% of the total patient population).
Although this high rate of resistant HSV disease does not seem to have been observed at many other centers, at least 3 European groups have recently noted the increasing importance of this problem [11, 12, 28] . One explanation for our findings could be our use of a more systematic search for the presence of HSV (mucocutaneous and gastrointestinal tract lesions and pneumonitis) and a more frequent susceptibility testing of the isolates. Other reasons might include differences in transplantation procedures, inducing a higher level of immunosuppression in recipients of unrelated grafts; 13 of the 14 patients in our series received such grafts. These 13 patients received fractionated total body irradiation and antithymocyte globulin in their conditioning regimen, and for 7 (54%) of them, T cell depletion by positive CD34 selection was performed. Lymphocyte subpopulation count data were too scarce to establish detailed relationships between immunologic status and clinical outcome. However, the median CD4 lymphocyte count for 8 evaluated patients was р1 cell/mm 3 . Moreover, 7 of 10 deaths were related to an infection (including 2 patients with EpsteinBarr virus-associated lymphoproliferation) that reflected profound immunodeficiency.
Recipients of unrelated bone marrow transplants suffer from protracted and profound deficiencies of CD4 and CD8 T cells, which have been shown to play a major role in the defense against HSV [31] [32] [33] . Small et al. [34] have reviewed the outcomes of 71 recipients of unrelated T cell-depleted bone marrow transplants who were conditioned with a combination of fractionated total body irradiation, chemotherapy, and antithymocyte globulin. Thirty-four percent developed a life-threatening opportunistic, mainly viral, infection. This group demonstrated that adults have a significantly increased risk of life-threatening opportunistic infections (compared with children) and that the rate of recovery of CD4 T cells correlates with the risk of developing these infections [34] . Furthermore, the risk was not correlated with the occurrence of GVHD. In the present series, only 5 patients had a history of GVHD before or at the time of their first episode of acyclovir-resistant HSV infection.
Because of the limited number of patients, no valid multivariate analysis of risk factors for resistant HSV infection could be elaborated [35] . Also, the retrospective nature of this study precluded any valid comparison with acyclovir-susceptible HSV infections, which were underreported during patient follow-up because of their late occurrence after transplantation and their usual benign course. Indeed, probable oropharyngeal (7 patients) or perineal (1 patient) acyclovir-susceptible herpetic infections were recorded in only 8 additional patients, all of whom were no longer receiving prophylactic acyclovir. The median interval from transplant to first clinical sign was 287 days. Pro- phylaxis with acyclovir or valacyclovir had been stopped for a median duration of 34 days. In 5 patients, the diagnosis was made only on clinical basis, and the patients were cured with empirical acyclovir treatment. A virological sampling was done in the 3 other patients and was positive for HSV-1. Acyclovir susceptibility was looked for (and proven) for only 1 patient, whose infection subsequently healed with acyclovir. The second patient was cured with foscarnet given for a concomitant CMV infection. The third patient was not evaluable because of early death caused by an unrelated complication. All patients except 1 had received a matched related graft. Prospective multicenter studies involving a higher number of patients are warranted to address the question of risk factors for resistant HSV infections, specifically in stem cell transplant recipients, and to compare these with risk factors for susceptible HSV infections. Such studies could address the question of specific roles for T cell depletion, low numbers of T cell subtypes, antithymocyte globulin use, GVHD, or the underlying diagnosis.
Our findings also raise questions about management of infection with drug-resistant HSV. First, increasing the acyclovir dosage to a maximum of 1500 mg/m 2 /day was never effective. To circumvent the risk of acyclovir-resistant HSV-1 emergence, withdrawing acyclovir primary prophylaxis from a high-risk patient group (yet to be fully delineated) is unlikely to solve all problems because severe acyclovir-sensitive infections could reappear. Second, prompt administration of foscarnet can cure some but not all infections in patients for whom acyclovir therapy fails. In the case of secondary resistance to foscarnet, combined or alternate use of acyclovir has been suggested to allow reversion of phenotypic resistance [21, 36] . However, this strategy is questionable because reversal of resistance was inconsistently observed in our study. Moreover, it would not solve the problem of primary combined resistance to acyclovir and foscarnet. In the case of combined acyclovir and foscarnet resistance, the only agent routinely available in practice is cidofovir, because no clinical strain resistant to cidofovir has been described. Our study confirms that treatment with this agent can be effective [29, 30, 37] . Cidofovir treatment has been followed by phenotypic reversion of acyclovir resistance in some reported cases [29] . Therefore, when a resistant HSV infection is clinically suspected, the combined or alternate use of cidofovir and acyclovir could be a useful strategy [29, 38] , pending the results of in vitro susceptibility testing.
Finally, drug susceptibility monitoring of serial specimens could be of help. A drawback of laboratory susceptibility testing is the waiting period before the results become available. Although our data must be interpreted with caution because of the limited number of patients, failure was associated in most cases with full or intermediate resistance in vitro. However, in vitro susceptibility to an agent was not always associated with clinical healing. This discrepancy, already described in AIDS patients [22, 39] , can be accounted for by host factors and the heterogeneity within populations of virus present in lesions, where drug-susceptible and drug-resistant strains may coexist [23, 40] . The awareness of this discrepancy should lead to rapid consideration of therapeutic modifications when herpetic lesions appear or persist despite the use of a given drug.
In conclusion, resistant HSV-1 diseases have become a concern in several allogeneic stem cell transplantation centers. Their reported incidence seems to be increasing, and they cause major morbidity and are potentially life-threatening. Foscarnet resistance may be associated with acyclovir resistance, even in the absence of previous foscarnet treatment. Laboratory investigations should be of prime importance in determining the true prevalence of resistant strains, in delineating factors associated with their emergence, in characterizing their genotypic alterations, and in guiding therapy. Current antiviral therapeutic schemes are not always efficient and new strategies are needed.
